|
|
Construction and in vitro research of the recombinant adenovirus vector AdOX40Ig |
CHEN Zhi-hong1, ZHAO Yuan-yuan2, ZHANG Shou-liang1, LIN Jian-yang1, WEI Fa-xing1, ZHU Wei2 |
(1.Department of General Surgery, the Affiliated People′s Hospital of Jiangsu University, Zhenjiang Jiangsu 212002; 2.School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang Jiangsu 212013, China) |
|
|
Abstract Objective: To construct and identify recombinant adenovirus vector containing the human OX40-IgG1 fusion gene, then to infect the HL-7702 liver cells to filter out the best infective dose and detect expression of OX40Ig,which lay a foundation for the immune therapy inhibitory after organ transplantation.Methods: Specific OX40 and hIgG1 Fc primers were designed according to GenBank, and subcloned into the pAdTrack-CMV shuttle plasmid after PCR and identification. Retransformed into BJ5183 competent cells with pAdeasy-1 by calcium chloride method. The recombinant plasmid was detected by PCR and DNA sequence analysis and was transfected into 293A cells. The recombinant adenovirus infected HL-7702 liver cells and filtered out the best infective dose. OX40Ig gene expression was detected by indirect immunofluorescence assay. OX40Ig protein expression was detected by ELISA.Results:pTOX40Ig and pAdOX40Ig were constructed successfully according to restriction endonuclease analysis. 293A cells were transfected, and then the purified recombinant adenovirus infected HL-7702 liver cells.10 MOI was the best infective dose.OX40Ig effective expression was detected in HL-7702 liver cells. Conclusion: The recombinant adenovirus vector AdOX40Ig carrying the human OX40-IgG1 fusion gene was successfully constructed, and OX40Ig effective expression was found in HL-7702 liver cells in vitro.
|
Received: 11 March 2012
|
|
|
|
[1] Pascual M, Theruvath T,Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation[J].N Engl J Med,2002,346(8):580-590.[2] Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation[J].Am J Transplant, 2006, 6(4):671-679. [3] Croft M.Control of immunity by the TNFR-related molecule OX40(CD134)[J].Annu Rev Immunol, 2010, 28:57-78.[4] Cavanagh MM,Hussell T. Is it wise to target the late costimulatory molecule OX40 as a therapeutic target?[J].Arch Immunol Ther Exp,2008, 56(5):291-297.[5] Sugamura K,Ishii N,Weinberg A,et al.Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40[J].Nat Rev Immunol,2004,4(6):420-431.[6] Kinnear G, Wood KJ, Marshall D,et al. Anti-OX40 prevents effector T-cell accumulation and CD8+T-cell mediated skin allograft rejection[J].Transplantation, 2010,90(12): 1265-1271.[7] 黄一虹,冯洒然,杜冰,等.移植物化学修饰与阻断 OX40-OX40L途径预防异基因骨髓移植小鼠移植物抗宿主病的研究[J].中华血液学杂志,2009,30(11):735-740.[8] Vincenti F. Chronic induction: what,s new in the pipeline[J].Contrib Nephrol, 2005 ,146:22-29.[9] 石向华,刘小友,孙煦勇,等.CD40阻断剂对大鼠肾移植急性排斥反应的影响[J].南方医科大学学报,2011,31(12):2085-2086.[10] Lunsford KE, Barbas AS, Brennan TV,et al. Recent advances in immunosuppressive therapy for prevention of renal allograft rejection[J].Curr Opin Organ Transplant, 2011, 16(4):390-397.[11] Sang W,Zhou C,Cheng N,et al. Control of mouse graftversushost disease following allogeneic bone marrow transplantation by blocking the CD28/B7 signaling pathway with lentiviral vector-mediated RNA interference[J].Immunol Lett, 2011, 136 (2): 194-202.[12] Aqarwal A,Newell KA. The role of positive costimulatory molecules in transplantation and tolerance[J].Curr Opin Organ Transplant,2008,13(4):366-372.[13] Sugamura K,Ishii N,Weinberg AD,et al. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40[J].Nat Rev Immunol,2004,4(6):420-431.[14] HonkanenScott M,Johnson J,Hering B,et al. Blockade of OX40 signals enhance survival of xenoislet grafts in spontaneously diabetic NOD mice[J].Transplant Proc, 2008,40(2):483-485.[15] Tavlor L,Schwarz H.Identification of a soluble OX40 isoform:development of a specific and quantitative immunoassay[J].J Immunol Methods,2001,255(1/2):67-72. |
|
|
|